Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds

Journal of Nanobiotechnology

Volumn 9, Issue , 2011, Pages

  Lara, Humberto H ^a   Garza Treviño, Elsa N ^b   Ixtepan Turrent, Liliana ^b   Singh, Dinesh K ^a  

^a WINSTON SALEM STATE UNIVERSITY   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Antibacterial agents; Bactericides; HIV AIDS; Silver Nanoparticles; Virucides

Indexed keywords

ANTIBACTERIAL AGENT; ANTIVIRAL THERAPY; BIOCIDAL; ENVELOPED VIRUS; HIV-1 INFECTIONS; HIV/AIDS; NANO SCALE; ORGAN CULTURE; POTENTIAL BENEFITS; SILVER NANOPARTICLES; VIRUCIDES;

BACTERICIDES; DISEASES; NANOPARTICLES; NANOTECHNOLOGY; VIRUSES;

SILVER;

118 D 24; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BACTERICIDE; GLYCOPROTEIN GP 120; INDINAVIR; INTEGRASE INHIBITOR; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PROTEINASE INHIBITOR; SILVER NANOPARTICLE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ZIDOVUDINE; ANTIINFECTIVE AGENT; METAL NANOPARTICLE; SILVER;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG MECHANISM; HEPATITIS B VIRUS; HUMAN; INFLUENZA VIRUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NANOTECHNOLOGY; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; VIRUS INHIBITION; BACTERIUM; CELL CULTURE; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; ULTRASTRUCTURE; UTERINE CERVIX;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BACTERIA; CELLS, CULTURED; CERVIX UTERI; FEMALE; HIV; HUMANS; METAL NANOPARTICLES; SILVER;

EID: 79961001550     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-9-30     Document Type: Review

References (61)

1. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, Kim SH, Park YK, Park YH, Hwang CY, Kim YK, Lee YS, Jeong DH, Cho MH. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007, 3:95-101.
2. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World Journal of Microbiology and Biotechnology 2010, 26:615-621.
3. Salata O. Applications of nanoparticles in biology and medicine. J Nanobiotechnology 2004, 2:3. 10.1186/1477-3155-2-3, 419715, 15119954.
4. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 2007, 3:168-171.
5. Catauro M, Raucci MG, De GF, Marotta A. Antibacterial and bioactive silver-containing Na2O × CaO × 2SiO2 glass prepared by sol-gel method. J Mater Sci Mater Med 2004, 15:831-837.
6. Crabtree JH, Burchette RJ, Siddiqi RA, Huen IT, Hadnott LL, Fishman A. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int 2003, 23:368-374.
7. Khare MD, Bukhari SS, Swann A, Spiers P, McLaren I, Myers J. Reduction of catheter-related colonisation by the use of a silver zeolite-impregnated central vascular catheter in adult critical care. J Infect 2007, 54:146-150. 10.1016/j.jinf.2006.03.002, 16678904.
8. Jain P, Pradeep T. Potential of silver nanoparticle-coated polyurethane foam as an antibacterial water filter. Biotechnol Bioeng 2005, 90:59-63. 10.1002/bit.20368, 15723325.
9. Lansdown AB. A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv Pharmacol Sci 2010, 2010:910686. 3003978, 21188244.
10. Kokura S, Handa O, Takagi T, Ishikawa T, Naito Y, Yoshikawa T. Silver nanoparticles as a safe preservative for use in cosmetics. Nanomedicine 2010, 6:570-574.
11. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, Yacaman MJ. The bactericidal effect of silver nanoparticles. Nanotechnology 2005, 16:2346-2353. 10.1088/0957-4484/16/10/059, 20818017.
12. Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol 2005, 153:521-525. 10.1111/j.1365-2133.2005.06490.x, 16120136.
13. Tanweer F, Hanif J. Re: Silver nitrate cauterisation, does concentration matter?. Clin Otolaryngol 2008, 33:503-504.
14. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, Goujard C, Debord T, Montagnier L. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996, 156:3509-3520.
15. Hoyme UB. Clinical significance of Crede's prophylaxis in germany at present. Infect Dis Obstet Gynecol 1993, 1:32-36. 10.1155/S1064744993000080, 2364679, 18476203.
16. George N, Faoagali J, Muller M. Silvazine (silver sulfadiazine and chlorhexidine) activity against 200 clinical isolates. Burns 1997, 23:493-495. 10.1016/S0305-4179(97)00047-8, 9429028.
17. Illingworth B, Bianco RW, Weisberg S. In vivo efficacy of silver-coated fabric against Staphylococcus epidermidis. J Heart Valve Dis 2000, 9:135-141.
18. Hoffmann S. Silver sulfadiazine: an antibacterial agent for topical use in burns. A review of the literature. Scand J Plast Reconstr Surg 1984, 18:119-126. 10.3109/02844318409057413, 6377481.
19. Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010, 8:1. 10.1186/1477-3155-8-1, 2818642, 20145735.
20. Furr JR, Russell AD, Turner TD, Andrews A. Antibacterial activity of Actisorb Plus, Actisorb and silver nitrate. J Hosp Infect 1994, 27:201-208. 10.1016/0195-6701(94)90128-7, 7963461.
21. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 2004, 275:177-182. 10.1016/j.jcis.2004.02.012, 15158396.
22. Gajbhiye M, Kesharwani J, Ingle A, Gade A, Rai M. Fungus-mediated synthesis of silver nanoparticles and their activity against pathogenic fungi in combination with fluconazole. Nanomedicine 2009, 5:382-386.
23. Chung YC, Chen IH, Chen CJ. The surface modification of silver nanoparticles by phosphoryl disulfides for improved biocompatibility and intracellular uptake. Biomaterials 2008, 29:1807-1816. 10.1016/j.biomaterials.2007.12.032, 18242693.
24. Liau SY, Read DC, Pugh WJ, Furr JR, Russell AD. Interaction of silver nitrate with readily identifiable groups: relationship to the antibacterial action of silver ions. Lett Appl Microbiol 1997, 25:279-283. 10.1046/j.1472-765X.1997.00219.x, 9351278.
25. Zhang G, Niu A, Peng S, Jiang M, Tu Y, Li M, Wu C. Formation of novel polymeric nanoparticles. Acc Chem Res 2001, 34:249-256. 10.1021/ar000011x, 11263883.
26. Lara HH, Ixtepan-Turrent L, Garza-Trevino EN, Rodriguez-Padilla C. PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J Nanobiotechnology 2010, 8:15. 10.1186/1477-3155-8-15, 2911397, 20626911.
27. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347. 10.1016/S0169-409X(02)00228-4, 12628320.
28. Mohanraj VJ, Chen Y, . (Eds) Nanoparticles. J Pharmaceutical Research 2006, 5:561-573. (Eds).
29. Kondow T, Mafune F. Structures and dynamics of molecules on liquid beam surfaces. Annu Rev Phys Chem 2000, 51:731-761. 10.1146/annurev.physchem.51.1.731, 11031298.
30. Greulich C, Kittler S, Epple M, Muhr G, Koller M. Studies on the biocompatibility and the interaction of silver nanoparticles with human mesenchymal stem cells (hMSCs). Langenbecks Arch Surg 2009, 394:495-502. 10.1007/s00423-009-0472-1, 19280220.
31. Yen HJ, Hsu SH, Tsai CL. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small 2009, 5:1553-1561. 10.1002/smll.200900126, 19326357.
32. Fukuoka A, Sakamoto Y, Guan S, Inagaki S, Sugimoto N, Fukushima Y, Hirahara K, Iijima S, Ichikawa M. Novel templating synthesis of necklace-shaped mono- and bimetallic nanowires in hybrid organic-inorganic mesoporous material. J Am Chem Soc 2001, 123:3373-3374. 10.1021/ja004067y, 11457076.
33. Baker C, Pradhan A, Pakstis L, Pochan DJ, Shah SI. Synthesis and antibacterial properties of silver nanoparticles. J Nanosci Nanotechnol 2005, 5:244-249. 10.1166/jnn.2005.034, 15853142.
34. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009, 27:76-83. 10.1016/j.biotechadv.2008.09.002, 18854209.
35. Yamanaka M, Hara K, Kudo J. Bactericidal actions of a silver ion solution on Escherichia coli, studied by energy-filtering transmission electron microscopy and proteomic analysis. Appl Environ Microbiol 2005, 71:7589-7593. 10.1128/AEM.71.11.7589-7593.2005, 1287701, 16269810.
36. Aymonier C, Schlotterbeck U, Antonietti L, Zacharias P, Thomann R, Tiller JC, Mecking S. Hybrids of silver nanoparticles with amphiphilic hyperbranched macromolecules exhibiting antimicrobial properties. Chem Commun (Camb) 2002, 3018-3019.
37. Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol 2007, 73:1712-1720. 10.1128/AEM.02218-06, 1828795, 17261510.
38. Asharani PV, Hande MP, Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC Cell Biol 2009, 10:65. 10.1186/1471-2121-10-65, 2759918, 19761582.
39. Lu L, Sun RW, Chen R, Hui CK, Ho CM, Luk JM, Lau GK, Che CM. Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther 2008, 13:253-262.
40. Mehrbod P, Motamed N, Tabatabaian M, Soleimani Estyar R, Amini E, Shahidi M. In Vitro Antiviral Effect of "Nanosilver" on Influenza Virus. DARU 2009, 17:88-93.
41. Ruparelia JP, Chatterjee AK, Duttagupta SP, Mukherji S. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater 2008, 4:707-716. 10.1016/j.actbio.2007.11.006, 18248860.
42. Amro NA, Kotra LP, Wadu-Mesthrige K, Bulychev A, Mobashery S, Liu G, . (Eds) High-resolution atomic force microscopy studies of the Escherichia coli outer membrane: structural basis for permeability. Langmuir 2000, 16:2789-2796. (Eds).
43. Danilczuk M, Lund A, Sadlo J, Yamada H, Michalik J. Conduction electron spin resonance of small silver particles. Spectrochim Acta A Mol Biomol Spectrosc 2006, 63:189-191. 10.1016/j.saa.2005.05.002, 15978868.
44. Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, Tam PK, Chiu JF, Che CM. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. J Proteome Res 2006, 5:916-924. 10.1021/pr0504079, 16602699.
45. Dibrov P, Dzioba J, Gosink KK, Hase CC. Chemiosmotic mechanism of antimicrobial activity of Ag(+) in Vibrio cholerae. Antimicrob Agents Chemother 2002, 46:2668-2670. 10.1128/AAC.46.8.2668-2670.2002, 127333, 12121953.
46. Li WR, Xie XB, Shi QS, Zeng HY, Ou-Yang YS, Chen YB. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol 2010, 85:1115-1122. 10.1007/s00253-009-2159-5, 19669753.
47. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005, 3:6. 10.1186/1477-3155-3-6, 1190212, 15987516.
48. Sun RW, Chen R, Chung NP, Ho CM, Lin CL, Che CM. Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells. Chem Commun (Camb) 2005, 5059-5061.
49. Borkow G, Gabbay J. Putting copper into action: copper-impregnated products with potent biocidal activities. FASEB J 2004, 18:1728-1730.
50. Speshock JL, Murdock RC, Braydich-Stolle LK, Schrand AM, Hussain SM. Interaction of silver nanoparticles with Tacaribe virus. J Nanobiotechnology 2010, 8:19. 10.1186/1477-3155-8-19, 2936366, 20718972.
51. Poon VK, Burd A. In vitro cytotoxity of silver: implication for clinical wound care. Burns 2004, 30:140-147. 10.1016/j.burns.2003.09.030, 15019121.
52. Wright JB, Lam K, Buret AG, Olson ME, Burrell RE. Early healing events in a porcine model of contaminated wounds: effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen 2002, 10:141-151. 10.1046/j.1524-475X.2002.10308.x, 12100375.
53. Tian J, Wong KK, Ho CM, Lok CN, Yu WY, Che CM, Chiu JF, Tam PK. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2007, 2:129-136. 10.1002/cmdc.200600171, 17075952.
54. Fahey JV, Wright JA, Shen L, Smith JM, Ghosh M, Rossoll RM, Wira CR. Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture. Mucosal Immunol 2008, 1:317-325. 10.1038/mi.2008.20, 19079193.
55. Wira CR, Fahey JV. The innate immune system: gatekeeper to the female reproductive tract. Immunology 2004, 111:13-15. 10.1111/j.1365-2567.2004.01796.x, 1782397, 14678193.
56. Cremel M, Berlier W, Hamzeh H, Cognasse F, Lawrence P, Genin C, Bernengo JC, Lambert C, Dieu-Nosjean MC, Delézay O. Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol 2005, 78:158-166. 10.1189/jlb.0305147, 15831560.
57. McGowan I. Microbicides: a new frontier in HIV prevention. Biologicals 2006, 34:241-255. 10.1016/j.biologicals.2006.08.002, 17097303.
58. Hsin YH, Chen CF, Huang S, Shih TS, Lai PS, Chueh PJ. The apoptotic effect of nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol Lett 2008, 179:130-139. 10.1016/j.toxlet.2008.04.015, 18547751.
59. Park EJ, Yi J, Kim Y, Choi K, Park K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol In Vitro 2010, 24:872-878. 10.1016/j.tiv.2009.12.001, 19969064.
60. Kawata K, Osawa M, Okabe S. In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells. Environ Sci Technol 2009, 43:6046-6051. 10.1021/es900754q, 19731716.
61. Miura N, Shinohara Y. Cytotoxic effect and apoptosis induction by silver nanoparticles in HeLa cells. Biochem Biophys Res Commun 2009, 390:733-737. 10.1016/j.bbrc.2009.10.039, 19836347.